RespireRx Pharmaceuticals Inc (CE) (RSPI) Quote

Seems obvious that is the plan

Maybe therein sits the strategy?

This EM market and zero liquidity is almost like a pseudo privately traded vehicle.

Lock-in partnership and funding then emerge like an IPO and create instant valuation?

Unreal. 
Hey Jeff, you do know you're a public company, not private correct?
Two years of filings now due and this is likely going to drag into year two of EM. 
Absolutely unacceptable when a simple form and filing fee can have this trading on otc pink current. 
Even the absolute scummy otc outright scams still manage to maintain a pink current status...

Thanks for the update. At this point I assume this won’t exit the EM until they have deal(s) in place. Would be interested to hear how they stand with SEC registration if they have extension to iron out all they need to get current and stay current per shareholder letter.

Thanks Big T. Much appreciated. EOM

Sent asking about Any updates Jeff could put out to the masses, a rough timeline to get this back trading , up dates on the IND , trials ?
Reply
They should have some updates shortly. Not with respect to trading, but with respect to other matters. GLTA

Yeah, I, Mr. Patient, is getting a bit impatient. Perhaps we will have a breakout with the new quarter?

I struggle with their course selection as well...

I think it would be beneficial for the moderators to sticky post the CEO/CSO interview from a year+ ago in regards to KRM-ll-81 as well as sticky post the shareholder letter. Those are both great communications to review and provide a general feel for their confidence and activities and the hidden tremendous value. Remember the insiders, execs, BOD, etc have a shit ton of equity riding on success. You can google the cost of delays in pharmaceutical development, so surely they will want to transition from IND enabling studies to working with partners on a phase 1 program ASAP as a prominent funding/partnership will open up several avenues of development that is currently stagnant. Time = money and they wont want this current status dragging on and possibly eroding value of their assets or allowing competitors to catch up.

We need shareholder updates please

Waiting is the hardest part....

They basically have stated they need additional funds to push the ampakine platform and SCI phase2 forward as well as additional funding for OSA platform which is also stalled for other reasons apparently since some funding is secured there but not yet able to be utilized.

So that really leaves their crown jewel KRM-ll-81 which is deep into NIH IND enabling studies, which supposedly in tier 3 well over a year now, so one would think with the accelerated intent of the NIH HEAL program that the preclincal effort should be almost completed. They need BP support to go into clinicals and would need to strike deals (license, partnership, sale has been their theme!), which judging by competitor activity with gabakine candidates that are similar and likely inferior to KRM-ll-81 that should be a no brainer. Just a matter of timing and who and what, IMO. I don't like this do nothing approach with the EM and presentation/communication, etc. My opinion is time is money and wasted time not building something of value is ridiculous. Even with timetables of preclinical efforts, I would think prepping your presentation and building resources including more stakeholders would be of value. The CSO and the science team here are extremely reputable and the assets, especially the selectivity profile of KRM-ll-81 is outstanding. So we wait on the beach.

Everyone is waiting for them to exit the otc sandbox and step onto the ocean beach where they can run to the ocean with arms wide open unlocking a world of possibilities and opportunities free from the boundaries of the sandbox...

This guy isn’t going to get this going anywhere, they have no money to do anything and he hasn’t the slightest clue how to raise capital. I hope I’m wrong but this is definitely what it seems

These guys are looking worse by the week. Starting to stink like typical otc shenanigans here. Should have known...

7 weeks since the shareholder letter, an update would be nice !!! Crickets.......

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of innovative treatments for psychiatric and neurological disorders. Based in Glen Rock, New Jersey, the company is working on a pipeline of new and repurposed drug products targeting conditions with significant unmet medical needs, such as epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases, and obstructive sleep apnea (OSA).

The company operates through two main drug platforms:

Neuromodulators: This includes GABAkines and AMPAkines, which are proprietary chemical entities designed to positively modulate GABAA receptors and AMPA-type glutamate receptors, respectively. These compounds aim to address disorders caused by disruptions in neuronal signaling. For example, their lead GABAkine has shown preclinical promise in pain relief, and their AMPAkine CX1739 is being studied for safety and efficacy in a Department of Defense-funded Phase 2 clinical trial announced in May 2024.

Pharmaceutical Cannabinoids: This platform includes dronabinol, a synthetic cannabinoid that interacts with the body’s endogenous cannabinoid receptors. RespireRx has established ResolutionRx Ltd., an Australian subsidiary formed in January 2023, to advance its obstructive sleep apnea drug development program.

Recent updates from RespireRx include a February 2025 letter from its CFO and CEO to stockholders and stakeholders, highlighting progress in their drug development efforts.

Additionally, the company has made strides in its leadership, appointing Dr. Dariusz Naziek to its board of directors in January 2024. RespireRx trades on the OTC Pink Market under the ticker symbol RSPI.

For the latest developments, such as specific clinical trial outcomes or financial performance, further details would typically be found in their SEC filings, like the Form 10-Q from September 2023 or the yet-to-be-filed 2023 annual report (Form 10-K). However, based on available information, RespireRx remains a small player in the biotech space, focusing on novel approaches to challenging medical conditions. Would you like me to dig deeper into any specific aspect of the company

Via this Google search
https://www.google.com/search?q=respirerx+pharmaceuticals&client=ms-android-verizon-us-rvc3&sca_esv=2104b54b03267c45&prmd=nmiv&sxsrf=AHTn8zps15SdWV9GLTjU5gKaJHbgJ4flsQ:1742865504470&source=lnt&tbs=qdr:w&sa=X&ved=2ahUKEwi566P6h6SMAxXQJzQIHRtQK4wQpwV6BAgDEAo&biw=360&bih=650&dpr=3

Found this on reddit
https://www.reddit.com/r/NooTopics/s/JXjBIKdQiR

Load up bro... LOLL

If you go to place an order with your brokerage, before confirming the order, it usually comes up with the L1, first up on bid/ask. Other than that, you can try using Interactive Brokers (IBKR) App. It also shows the L1. It's a bit wonky, but mostly accurate, if you're into trading these types of stocks.

Hey Lime - where are you getting that b/a as I’m in Canada and trading it but still can’t “see” a bid ask ?

.0008 x .0018

I have to admit these clowns are running a fine company straight into the ground!!!

I am not sure anyone disagrees with this comment....

"They have a fiduciary duty and obligation to shareholders and they aren't meeting it."

It is clear to me that they have something significant and quite possibily "breakthrough" level candidate with KRM-ll-81. One only has to read the commentary in their publications as well as competitor publications and activity and it suggests that KRM-ll-81 might just have the superior preclinical selectivity profile for gabakines. And of course harken back to the CSO interview related to this announcement and the move into tier 3 NIH HEAL program and easily the excitement is there from the CSO! They have and apparently continue to struggle to get traction for both the OSA program and ampakine platform even with the DOD funding hanging out there. Both have potential, but that has been known for a long time and stalled for various reasons I assume. All this talk about creating preferred and phantom shares as well as moving to institutional and insider support with attached warrants all started however when the gabakine got traction with the NIH. So, they have huge equity linked to success here which is great.

I think the consternation centers around being on the OTC and now the EM of all places with an abandonment of the website and lack of professional tact with presentation and communications. Does this approach get the best deals for any assets? Does this approach attract the needed resources? I don't know, maybe I am too much of a purest and do the right thing mentality. I probably should just focus my energy elsewhere and just smile and wave when they sign a huge deal sooner or later and this thing runs wild past .10, .20, .30 like so many storied pharma stocks of the OTC and NASDAQ for that matter. And really the thing is, this one may actually have something very premier backing their story! Good luck to all of us investors and our little support group here! LOL.

They chose to be a publicly traded company. 
If it "wasn't a concern" of theirs to meet those requirements, stay current and not only be relegated to the Expert Market, but REMAIN there going on nearly a year now, then they shouldn't have gone public in the first place. They also claimed they would regularly keep shareholders up to date while in EM, which they haven't done either. As many of us pointed out last June, there was and still is an inexpensive pathway to remaining pink current and trading on the open market that doesnt require the funds that SEC reporting does, and they have either ignorantly or willfully ignored that path. 
They have a fiduciary duty and obligation to shareholders and they aren't meeting it. Regardless of their pipeline potential, this current situation is unacceptable. 

How much longer is reasonable?

You do understand the viewpoint SHARED here.. that it is unreasonable to not have a financial filing since late 2023.
Or not having up-to-date information on the website which is years out of date as well.
Or allow your publicly traded company to be on this "Expert" market for what 9 months now.
Or have a lack of professional appearance.
And also complain about fundraising difficulties....

So we just watch and wait for these guys to emerge with the massive deals to get KRM-ll-81 into clinicals and see the stock trading 100x these peanuts level. Got it.

"I just don't see how the current approach is helping to build support and resources to capitalize on these assets for the benefit of ALL stakeholders." I just don't see with all the extraordinary molecules in RSPI's pipeline that this is a currently a concern. It is getting the best deals possible - we will benefit in the long run. I am willing to bet the longer (within reason) we wait, the better the outcome. Wait a minute... I am betting!

I am with ya and it is more than fair to be skeptical here especially with the path chosen following huge volume for 2 days around the DOD news and then an accumulating selloff for two weeks leading into the EM. Lots of positioning for sure!

I have read as much detail as I can find in regards to publications and past SEC filings to be a firm believer that they have the assets. I just don't see how the current approach is helping to build support and resources to capitalize on these assets for the benefit of ALL stakeholders.

I've waited a year at this point and I don't mind waiting longer. I'm just very skeptical and don't trust anything in the otc after having been through the ENZC mess for four years before coming over here. 

I know. Which makes me wonder if this ever comes back to the OTC until AFTER a major deal is announced. This way institutional can absorb shares at various price points until this exits the EM eventually at prices well into the pennies... Retail cannot easily buy now, but current retail can exit positions if "experts" start accumulating. Or maybe they just distribute share ownership to a newco for all current stakeholders.

Surely whomever is going to fund or partner here will want their own management team capable of bringing assets into and through clincal stages.

I'm talking about retail shareholders. 

I don't know. All the insiders have a sh-- ton riding on how the company performs BOTH in terms of securing payment level events and the stock price itself as it impacts the value of the preferred and phantom stock as well as the warrants outstanding.

"Probably trying to flush out as many shareholders as possible at this point." This would be the dumbest strategy and completely risk fumbling this unbelievable opportunity with a premier asset away. IMO, they have the lead/most promising gabakine for the industry, and other publications point to the selectivity profile of KRM-ll-81. I doubt they are going to want the competition to catch up here.

Possibly for KRM-ll-81 and there are many examples of major BP preclinical deals out there. Considering that KRM-ll-81 is showing efficacy for BOTH pain and epilepsy indications, there could be multiple BP's involved to slide clinical development into their pipelines.

I just don't see the Respire team having the clinical expertise, this team appears to be more on the discovery end of things.

Whatever is going on, it's clear that they do not want retail shareholders in this. They owe two years worth of filings now, and this is closing in fast on one year being untradeable on the EM. Probably trying to flush out as many shareholders as possible at this point. 

LT - Reviewing Lippa's credentials where he has also been involved with venture capital firms suggests to me that he has a firm understanding of the values of all the molecules RSPI control. I believe Jeff Margolis also. The huge potential for so many of these molecules is mind blowing. Take CX546 - not mentioned is its possible use in cardiac surgery patients where neurological issues frequently occur post-surgery. I'm guessing there are multiple mega-pharmas vying for these molecules. A bidding war is occurring?

Many dots can be connected when one spends maybe 40 hours or so reviewing all the publications related to KRM-ll-81 and then review competitive/similar gabakine compounds and related publications and what competitors are doing and saying about forward motion in that regards.

Due diligence and investor are congruent labels.

I hope BP takes over the entirety of the gabakine platform here. Move that premier asset to another exchange in more capable hands and isolated from the junior high wing of the investment world. It is crucial to momentum for those patients who can benefit from improved pain or epilepsy therapy/medicine which I believe they are onto it. GLTA.

Is it any wonder....

"Jeff Margolis, and Arnold Lippa, each an officer and a director of RespireRx received awards of 120,000,000 and 70,000,000 shares of Phantom Stock, respectively. Our independent director, Joseph R. Siegelbaum was awarded 20,000,000 shares of Phantom Stock. The remaining 96,000,000 of shares of Phantom Stock awarded were awarded to five vendors, consultants, advisors or their designees, one of which is an affiliate. A total of 306,000,000 shares of Phantom Stock were awarded"

"Phantom Stock Award Agreements do not provide for distributions or anti-dilution protections"..

Couple this with the terms of the preferred shares and they have ALOT tied to successful PAYMENT EVENTS with payout levels linked to price of common stock. So it is no wonder they want to minimize dilution and have pushed the preferred.

They stopped issuing shares a year ago. The OS is less than half the AS. Even when the price shot up 750% they did not turn on the spigot. That’s quite significant.

the only truth!

tards are still here?

Another way to look at the due diligence related to KRM-ll-81 is what have competitors been doing/saying with similar gabakines…

Have read multiple publications and indications that the future of gabakine development is going to essentially target compound design in the fashion of what selectivity profile that KRM-ll-81 has in place. So it is guaranteed BP is following this very closely and with a wide range of medical indications (various pain, various epilepsy) there might just be multiple BP interested here. I think they might have just stumbled upon a gold mine here and they need BP help to get this into clinicals and exploit the potential.

Thanks for your input. I really do hope these guys can get themselves to a point where they can pursue the ampakine platform in a deeper and more meaningful way, i.e. open that zoo of compounds. Right now it is clear this is all about the gabakine platform and getting KRM-ll-81 into clinicals as it should be!

They should be in a window of time that I would guess where they get final word on the SBIR grant for pursuing IND enablement for epilepsy trials as well as in a window of time for tier 3 NIH preclincals/IND enabling studies wrapping up for pain indications and logical speculation is that they are looking for major partnerships to initiate a phase 1 trial.

KRM-ll-81 by all accounts is a premier asset readying for multiple lucrative clinical pathways (pain and epilepsy). The implications are astounding. Which makes the current equity status curious. The longer this status drags on really makes one wonder if they won't just announce big news items while on the EM! It could easily be sitting at a nickel or dime by the time this exits EM, unless of course they just spin out equity ownership of the gabakine into a newco for all current stakeholders or something along that lines.

Curious. This just popped up in my daily Google search. A bit old, but a reminder of another ampakine with enormous potential -

Compound Shown to Reduce Brain Damage Caused by Anesthesia in Animal Model

JUNE 22, 2016

An experimental drug prevented learning deficits in young mice exposed repeatedly to anesthesia, according to a study led by researchers from NYU Langone Medical Center and published as the cover story of Science Translational Medicine on June 22.
The study results may have implications for children who must have several surgeries, and so are exposed repeatedly to general anesthesia. Past studies have linked such exposure to a higher incidence of learning disabilities, attention deficits, and hyperactivity.
Specifically, the research team found that the experimental drug CX546, part of the AMPAkine class in clinical trials for several neurological conditions, counters for the dampening effect of anesthesia on nerve signaling. The treatment bolstered nerve cell activity as well as learning ability in mice recovering from repeated exposure to general anesthesia.
“Each year, in the United States alone, more than a million children under age four undergo surgical procedures that require anesthesia, and the numbers are growing,” says the study’s senior investigator Guang Yang, PhD, an assistant professor of anesthesiology at NYU Langone. “There are currently no effective treatments to combat potential toxicity linked to repeated anesthesia, and we would like to change that.”
Yang’s group took advantage of genetically engineered young mice that have protein markers which glow in response to changes in nerve function. Researchers then used advanced microscopy to visualize activity in their brains, comparing nerve signaling activity in those exposed to anesthesia to those who were not.
The research team found that anesthesia exposure resulted in a prolonged reduction of signal transmission among nerve cells following anesthesia. They also observed that CX546 treatment enhances this transmission, along with learning and memory in mice exposed to anesthesia.
The team studied the anesthetic ketamine, which blocks NMDA (N-methyl-D-aspartate) receptor proteins that enable charged particles like calcium to flow into nerve cells, like electric switches that trigger and shape messages. In contrast, CX546 increases nerve cell activity and calcium influx into nerve cells by enhancing the activity of proteins called AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors.
“We were able to counter anesthesia-induced deficits in the formation of connections between nerve cells and related learning problems,” says Yang. “This work is an important proof-of-principle study, and opens the door to a new direction for preventing long-term neurocognitive deficits.”
Along with Yang, NYU Langone study co-authors were Lianyan Huang, Joseph Cichon, and Ipe Ninan. The authors were also associated with the Medical Scientist Training Program and the Department of Psychiatry at New York University School of Medicine. Research funding for the work came from National Institutes of Health grants GM107469, AG048410, and HD076914.

It absolutely will because it has to.

No point in talking about applying for any further grants or in-licensing more compounds or even executing on the current DOD grant funding or the SBIR grant funding for epilepsy until they start making funding deals and asset partnerships AND become a more professional company. Everyone is watching and waiting.

Yes that would be monumental

Well they stated...

"As discussed above, potential strategic deal making discussions that commenced in 2024, continue into 2025."
And
"We intend to enter into at least one strategic transaction."

It is only logical by their actions and the current status of their candidates, especially the gabakine exiting NIH HEAL program that they are looking for and positioning for a large transformative deal. 2025 is 1/4 of the way over so remainder of year could be exciting once they let this racehorse out of the gate...

Like everything else, that looks to be older and not updated information.

Curious if they intend to update the OS or if we have any idea how many shares would be fully diluted status here.

Well they stated...

"As discussed above, potential strategic deal making discussions that commenced in 2024, continue into 2025."
And
"We intend to enter into at least one strategic transaction."

It is only logical by their actions and the current status of their candidates, especially the gabakine exiting NIH HEAL program that they are looking for and positioning for a large transformative deal. 2025 is 1/4 of the way over so remainder of year could be exciting once they let this racehorse out of the gate...

https://pitchbook.com/profiles/company/41040-55#overview

They must have something Big lined up !


Well, isn't it obvious?

They must not need or desire retail investors. What pharmaceutical company or any legit company for that matter has an abandoned website, zero PR/filing updates, zero clarity on direction and desires to trade on the EM??? AND... works with the DOD and at advanced stages with the NIH for grants as well as deep into the NIH HEAL program progression??

And yet, 700 million shares somehow traded over only 2 days on the DOD phase 2 funding?? And the last 2 weeks before entering EM 350 million shares traded!

Hmmm..

On the positive side,

Whether they considered this upon choosing this fantastic EM route or not, is that most investors are now in LONG term holdings if you have been following this for the past few years.. and the time period has proven even moreso how valuable these assets are... and nobody is now going to be walking away from this for merely peanuts....

Acadia and Saniona huge deal for "SAN711 is a first-in-class, highly selective GABAA-a3 positive allosteric modulator".
Incannex continues to advance their dronabinol compound for OSA.

In both instances IMO RSPI's assets are likely superior. And of course the fledgling ampakine program from the old days here may indeed eventually get new life if they ever get that phase 2 off the ground and running!

Yeah that's the reason we all waiting it out and tolerating their